Breast Cancer: Epidemiological Panorama and Opportunities for Prevention

  • Nancy Reynoso-Noveron
  • Alejandro Mohar-Betancourt


At present, breast cancer (BC) is the most frequently found malignant tumor among women throughout the world. It is the first cause of death for this population group and one of the diseases with greatest social and economic impact in our times. While the causes and natural history have not been completely defined, it is acknowledged that genetic and reproductive factors besides lifestyles are the principal risk factors for the development of BC. A rare type of cancer with onset in young women is the inflammatory breast cancer (IBC), the epidemiological information of which is limited, is frequently associated with conditions such as obesity arising from unhealthy lifestyles. In addition to strengthening early detection, it is necessary to promote epidemiological research and implementation of strategies to prevent those potentially modifiable factors, with the aim of reducing the global burden of BC, specifically in types as aggressive as the IBC.


Breast Cancer Inflammatory Breast Cancer Uterine Cervix Develop Breast Cancer Conservative Breast Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    World Health Organization WHO. International Agency for Research of Cancer. World cancer report. Lyon: IARC Press; 2008. p. 260.Google Scholar
  2. 2.
    Cotran RS, Robbins SL, Kumar V. Patología estructural y funcional. 6th ed. Madrid: McGraw-Hill; 1999.Google Scholar
  3. 3.
    Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer incidence in five continents, vols. 1–8. IARC Cancer Base no. 6. Lyon: IARC Press. Available at: ( Accessed 25 Nov 2009.
  4. 4.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar
  5. 5.
    Organización Mundial de la Salud. Cáncer 2008. Available at: ( Accessed 25 Oct 2009.
  6. 6.
    Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER cancer statistics review. Bethesda: National Cancer Institute; 2004. p. 1975–2001. Available at: ( Accessed 11 Apr 2005.Google Scholar
  7. 7.
    Robles SC, Galanis E. Breast cancer in Latin America and the Caribbean. Rev Panam Salud Publica/Pan Am J Public Health. 2002;11(3):178–84.CrossRefGoogle Scholar
  8. 8.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC Cancer Base no. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: ( Accessed on 9th December 2011.
  9. 9.
    Geddes M, Parkin DM, Khlat M, Balzi D, Buiatti E, editors. Cancer in Italian migrant populations. Scientific publication no. 123. Lyon: IARC Press; 1993.Google Scholar
  10. 10.
    Tyczynski J, Tarkowski W, Parkin DM, Zatonski W. Cancer mortality among Polish migrants to Australia. Eur J Cancer. 1994;30A:478–84.PubMedCrossRefGoogle Scholar
  11. 11.
    Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993;85:1819–27.PubMedCrossRefGoogle Scholar
  12. 12.
    Kelsey JL, Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 1996;17:47–67.PubMedCrossRefGoogle Scholar
  13. 13.
    International Agency for Research on Cancer. GLOBOCAN 2002. Available at: ( Accessed 18 Oct 2008.
  14. 14.
    González-Pier E, Gutiérrez-Delgado C, Stevens G, Barraza-Lloréns M, Porras-Condey R, Carvalho N, et al. Definición de prioridades para las intervenciones de salud en el Sistema de Protección Social en Salud de México. Salud Publica Mex. 2007;49(Supl 1):S37–52.PubMedGoogle Scholar
  15. 15.
    Rodríguez-Cuevas S, Macías CG, Franceschi D, Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer. 2001;91:863–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Forbes JF. The incidence of breast cancer: the global burden, public health considerations. Semin Oncol. 1997;24(1, Suppl 1):S1–20, S1–S35.Google Scholar
  17. 17.
    Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358:1389–99.CrossRefGoogle Scholar
  18. 18.
    Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4:665–76.PubMedCrossRefGoogle Scholar
  20. 20.
    Trichopoulos D. Is breast cancer initiated in utero? Epidemiology. 1990;1:95–6.PubMedGoogle Scholar
  21. 21.
    Ahlgren M, Sorensen T, Wohlfahrt J, Haflidadottir A, Holst C, Melbye M. Birth weight and risk of breast cancer in a cohort of 106,504 women. Int J Cancer. 2003;107:997–1000.PubMedCrossRefGoogle Scholar
  22. 22.
    McCormack VA, Silva IDS, Stavola BLD, Mohsen R, León DA, Lithell HO. Fetal growth and subsequent risk of breast cancer: results from long term follow up of Swedish cohort. BMJ. 2003;326:248–53.PubMedCrossRefGoogle Scholar
  23. 23.
    Vatten LJ, Maehle BO, Nilsen TLL, Tretli S, Hsieh C, Trichopoulos D, Stuver SO. Birth weight as a predictor of breast cancer: a case control study in Norway. Br J Cancer. 2002;86:89–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding. Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease. Lancet. 2002;360:187–95.CrossRefGoogle Scholar
  25. 25.
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives. Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast cancer. Lancet. 1996;347:1713–27.CrossRefGoogle Scholar
  26. 26.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–12.CrossRefGoogle Scholar
  28. 28.
    Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer- collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87:1234–345.CrossRefGoogle Scholar
  29. 29.
    Trentham-Dietz A, Newcomb PA, Storer BE, et al. Body size and risk of breast cancer. Am J Epidemiol. 1997;145:1011–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. N Engl J Med. 1997;336:1269–75.PubMedCrossRefGoogle Scholar
  31. 31.
    Freudenheim JL, Marshall JR, Vena JE, et al. Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients. J Natl Cancer Inst. 1996;88:340–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004;96:1152–560.PubMedCrossRefGoogle Scholar
  33. 33.
    Key TJ, Allen NE, Spencer EA, Travis RC. Nutrition and breast cancer. Breast. 2003;12:412–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Henderson BE, Bernstein L. The international variation in breast cancer rates: an epidemiological assessment. Breast Cancer Res Treat. 1991;18 Suppl 1:S11–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Commission of the European Communities. European guidelines for quality assurance in mammography screening, Europe against cancer programme. 3rd ed. Luxembourg: Office for Official Publications of the European Communities; 2001.Google Scholar
  36. 36.
    D’Orsi CJ, et al. Breast imaging reporting and data system (BI-RADS). 4th ed. Reston: ACR; 2003.Google Scholar
  37. 37.
    Sant M, Allemani C, Capocaccia R, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003;106(3):416–22.PubMedCrossRefGoogle Scholar
  38. 38.
    Horner MJ, Ries LAG, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2006. Bethesda: National Cancer Institute; 2009. Available at:, based on November 2008 SEER data submission posted on the SEER web site. Accessed Dec 2011.Google Scholar
  39. 39.
    Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Smedley B, Stith A, Nelson A, editors. Unequal treatment: confronting racial and ethnic disparities in health care, Committee on understanding and eliminating racial and ethnic disparities in health care. Washington, D.C.: Institute of Medicine/National Academy Press; 2002.Google Scholar
  41. 41.
    Commission on Cancer – National Cancer Database. Benchmark reports, V 8.0 – 20 Aug, 2007 – STAGE of breast cancer diagnosed in 2004. Commission on Cancer – National Cancer Database (NCDB); 2007.Google Scholar
  42. 42.
    El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer (Abstract). BMC Cancer. 2006;6:194.PubMedCrossRefGoogle Scholar
  43. 43.
    Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol. 2005;16(2):263–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer. 2004;91(1):77–83.PubMedCrossRefGoogle Scholar
  45. 45.
    Schneider C, Fehr MK, Steiner RA, Hagen D, Haller U, Fink D. Frequency and distribution pattern of distant metastases in breast cancer patients at the time of primary presentation. Arch Gynecol Obstet. 2003;269(1):9–12.PubMedCrossRefGoogle Scholar
  46. 46.
    Traina A, Cusimano R, Liquori M, et al. Breast cancer incidence in the city and province of Palermo in 1999–2002: a breast cancer registry report. Ann N Y Acad Sci. 2004;1028:473–80.PubMedCrossRefGoogle Scholar
  47. 47.
    Efficace F, Biganzoli L, Piccart M, et al. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer. 2004;40(7):1021–30.PubMedCrossRefGoogle Scholar
  48. 48.
    Secretaría de Salud. Subsecretaría de Prevención y Promoción de la Salud. Programa de Acción Específico 2007–2012: Cáncer de mama.Google Scholar
  49. 49.
    Ortega-Altamirano D, López-Cervantes M. Estrategias de la enseñanza de auto examen del Seno en mujeres en edad reproductiva. Salud Publica Mex. 2000;42:17–25.PubMedCrossRefGoogle Scholar
  50. 50.
    Millar AB. What is the role of early detection and screening in cancer control? J Public Health Policy. 1993;14(4):403–11.CrossRefGoogle Scholar
  51. 51.
    Advisory Committee on Breast Cancer Screening. Screening for breast cancer in England: past and future. NHSBSP publication no. 61. Perth: Typeset by Prepress Projects Ltd. 2006. Available at: ( Accessed Oct 2008.
  52. 52.
    Tabar L, Yen MF, Vitak B, Chen HHT, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction and screening. Lancet. 2003;361:1405–10.PubMedCrossRefGoogle Scholar
  53. 53.
    NOM-041-SSA2-2002, Para la prevención, diagnóstico, tratamiento, control y vigilancia epidemiológica del cancer de mama. Diario Oficial, 17 Sept 2003.Google Scholar
  54. 54.
    Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(5 Part 1):347–60.PubMedGoogle Scholar
  55. 55.
    Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med. 2003;348(17):1672–80.PubMedCrossRefGoogle Scholar
  56. 56.
    Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353(17):1773–83 [Epub 2005 Sep 16].PubMedCrossRefGoogle Scholar
  57. 57.
    Olsen O, Gozsche PC. Cochrane review on screening for breast cancer with mammography. Lancet. 2001;358:1340–2.PubMedCrossRefGoogle Scholar
  58. 58.
    Canadian Cancer Society/National Cancer Institute of Canada. Canadian cancer statistics 2006. Toronto. 2006. Available at: ( Accessed Dec 2010.
  59. 59.
    Nass S, Ball J, Committee on Improving Mammography Quality Standards, National Cancer Policy Board, Institute of Medicine and National Research Council of the National Academies, editors. Improving breast imaging quality standards. Washington, D.C.: The National Academies Press; 2005.Google Scholar
  60. 60.
    Preventive Services Task Force. Screening for breast cancer. U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716–26.Google Scholar
  61. 61.
    Andrieu N, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 Carrier Cohort Study: a report from the EMBRACE, GENESPO, GEO-HEBON, and IBCCS Collaborator’s Group. J Clin Oncol. 2006;24:3361–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Smith Robert A, et al. American cancer society guidelines for breast cancer screening: update 2003. CA Cancer J Clin. 2003;54:141–69.CrossRefGoogle Scholar
  63. 63.
    Mishra SI, Bastani R, Crespi CM, Chang LC, Luc PH, Baquet CR. Results of a randomized trial to increase mammogram usage among Samoan women. Cancer Epidemiol Biomarkers Prev. 2007;16:2594–604.PubMedCrossRefGoogle Scholar
  64. 64.
    Bailey E, Erwin D, Belin P. Using cultural beliefs and patterns to improve mammography utilization among African American women: the witness project. J Natl Med Assoc. 2000;92:136–42.PubMedGoogle Scholar
  65. 65.
    Nigenda G, Caballero M, González-Robledo LM. Barreras de acceso al diagnóstico temprano del cáncer de mama en el Distrito Federal y en Oaxaca. Salud Publica Mex. 2009;51(Supl 2):S254–62.PubMedGoogle Scholar
  66. 66.
    Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the Use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27(19):3235–58.PubMedCrossRefGoogle Scholar
  67. 67.
    Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer- 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99(4):272–82.PubMedCrossRefGoogle Scholar
  68. 68.
    Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41.PubMedCrossRefGoogle Scholar
  69. 69.
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77–84.PubMedCrossRefGoogle Scholar
  70. 70.
    Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616–22.PubMedCrossRefGoogle Scholar
  72. 72.
    Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609–15.PubMedCrossRefGoogle Scholar
  73. 73.
    Levine P, Veneroso C. Epidemiology of inflammatory of breast cancer. Semin Oncol. 2008;35(1):11–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Nancy Reynoso-Noveron
    • 1
  • Alejandro Mohar-Betancourt
    • 2
  1. 1.Unidad de Investigación Biomédica en CáncerInstituto Nacional de Cancerología (INCan), Universidad Nacional Autónoma de México (UNAM)Mexico CityMexico
  2. 2.Department of General DirectionInstituto Nacional de CancerologíaTlalpan, Mexico CityMexico

Personalised recommendations